PROM1 and glioblastoma: Thus, it requires a caution in evaluating the clinical impact of features that are associated with the tumor purity and stromal signature levels as we have observed for the impact of stromal signature on clinical outcomes dominates those of CD133 signature levels for at least three cancer types such as GC along with GBM and kidney cancers.